KFF April 24, 2024
In a new analysis, KFF finds that 3.6 million people with Medicare could be eligible for coverage of Wegovy (semaglutide) now that the Food and Drug Administration has approved the use of the anti-obesity drug to reduce the risk of heart attacks and stroke in certain patients.
This change potentially allows access to Wegovy for just over 1 in 4 of the 13.7 million people on Medicare diagnosed with obesity or overweight, based on data from 2020, the analysis shows.
Based on KFF research, about 7% of beneficiaries, or 3.6 million people, had established cardiovascular disease and obesity or overweight in 2020 and could be eligible for coverage of Wegovy to reduce the risk of serious heart problems. (Among this...
Today's Sponsors
Today's Sponsor